143
Views
0
CrossRef citations to date
0
Altmetric
Meta-analysis

Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies

ORCID Icon & ORCID Icon
Pages 1027-1040 | Received 13 Feb 2023, Accepted 14 Aug 2023, Published online: 28 Aug 2023
 

ABSTRACT

Objective

To systematically review the cost-utility evidence of TNF-a-i treatment for rheumatoid arthritis (RA) and to estimate the pooled incremental net benefit (INBp).

Methods

We selected economic evaluation studies reporting the cost-utility of TNF-a-i compared to other disease-modifying anti-rheumatic drugs (DMARDs) after a systematic search in PubMed, Embase, Scopus, and Tufts Medical Centers’ cost-effective analysis registry. The results were reported as pooled INB in purchasing power parity-adjusted US dollars, along with 95% confidence intervals. We used GRADE quality assessment to present summaries of evidence and random-effects meta-analysis to synthesize cost-utility of TNF-a-i.

Results

We included 86 studies for systematic review, of which 27 for meta-analysis. TNF-a-i is not cost-effective [$ −4,129(−6,789 to −1,469)] compared to other DMARDs but with high heterogeneity. There was no evidence of publication bias (p = 0.447). On separate analysis, TNF-a-i is not cost-effective [$ −4,805(−7,882 to −1,728)] compared to conventional synthetic DMARDs for RA treatment. GRADE assessment indicated very low confidence in pooled cost-utility results and likely presence of risk of bias on the overall ECOBIAS checklist in studies.

Conclusion

Based on the available evidence during the study period, TNF-a-i is not a cost-effective option for treating RA compared to other DMARDs. However, high heterogeneity and low confidence in GRADE quality assessment preclude the results from being generalizable.

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contribution

S Kumar: Data curation, original draft. B Bagepally: Conceptualisation, Data curation, Formal analysis, review & editing. All authors read and approved the final version of the manuscript for publication.

Supplementary Material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/14737167.2023.2249610

Additional information

Funding

The authors received no specific funding for this work. However, the Dept. of Health Research, Govt. of India funds the Health Technology Assessment resource center ICMR-NIE. Funders had no role in the study conceptualization, conduction, and manuscript preparation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.